Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592124 · ClinicalTrials.gov registry record · Phase 2
Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 7
- Study locations
NCT00592124 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 168 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00592124, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 7
- Study locations
Study Summary
A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) is an oral, FDA-approved, anti-HIV drug, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the adherence and acceptability to and blood levels of three daily regimens of tenofovir in both oral and gel form.
Conditions Studied
Interventions
- DRUG Tenofovir disoproxil fumarate
- DRUG Tenofovir gel
Study Locations (7)
KwaZulu-Natal
- Botha's Hill CRS - Durban
- Umkomaas CRS - Durban
Alabama
- Alabama Microbicide CRS - Birmingham
New York
- Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS) - The Bronx
Ohio
- Case CRS - Cleveland
Pennsylvania
- Pitt CRS - Pittsburgh
Other
- Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS - Kampala
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592124
The ClinicalTrials.gov registry entry for NCT00592124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir disoproxil fumarate is the first listed.
NCT00592124 reports 7 study locations spanning 6 distinct geographic areas - top geographies include KwaZulu-Natal, Alabama, New York.
Frequently Asked Questions
What is clinical trial NCT00592124 about?
NCT00592124 is a clinical study titled "Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women". A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) is an oral, FDA-approved, anti-HIV drug, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the adher...
What is the current status of trial NCT00592124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2008-06. Estimated completion is 2010-07.
What conditions does trial NCT00592124 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00592124?
The interventions under investigation include: Tenofovir disoproxil fumarate (DRUG), Tenofovir gel (DRUG).
Who is sponsoring clinical trial NCT00592124?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00592124 being conducted?
This trial has 7 study locations across Alabama, New York, Ohio, Pennsylvania, KwaZulu-Natal. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.